Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
2024年7月26日 - 8:00PM
ビジネスワイヤ(英語)
H.U. Group Holdings Inc. and its wholly-owned subsidiary
Fujirebio today announced the availability of the Lumipulse G GFAP
assay for the fully automated, random-access LUMIPULSE® G
immunoassay systems. The Research Use Only (RUO) assay is now
available in the United States, and it will be available in Japan,
Europe and other regions* as of September this year. The
Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the
quantitative measurement of glial fibrillary acidic protein (GFAP)
in human plasma and serum in just 35 minutes.
“In 2023 we already introduced two new important neuro assays
for RUO-based detection of Neurofilament Light (NfL) and pTau 217,”
said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc.
“We continue our engagement in biomarker-based testing for
neurological diseases with the Lumipulse G GFAP, affirming our
commitment to play an essential partnering role in both research
and clinical routine.”
The Lumipulse G GFAP assay will allow the scientific community
and clinical research professionals to further study and understand
the potential clinical utility of this promising astrocytic
biomarker for neurological conditions such as multiple sclerosis,
Alzheimer’s disease, Parkinson’s disease, and brain-related acute
traumatic injuries or stroke.1
With the fully automated random-access LUMIPULSE G platform,
professionals will be able to measure GFAP in a user-friendly and
reliable way. This standardized immunoassay platform is already
widely available in labs for routine and research testing of
neurological disease-related biomarkers. The new assay meets the
necessary quality, throughput, and regulatory requirements to
support potential routine testing of GFAP in combination with other
tests from the Fujirebio neuro biomarker menu.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global
leader in high-quality in vitro diagnostics (IVD) testing with more
than 50 years’ accumulated experience in the research, development,
production and worldwide commercialization of robust IVD
products.
Fujirebio was the first company to develop and market
cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand
over 25 years ago. Fujirebio offers a comprehensive line-up of
manual and fully automated assays for neurological diseases and
consistently partners with organizations and clinical experts
across the world to develop new pathways for earlier, easier and
more complete neurodegenerative diagnostic tools. More information
can be found at www.fujirebio.com/neuro.
References:
- Abdelhak, A., Foschi, M., Abu-Rumeileh, S. et al. Blood GFAP as
an emerging biomarker in brain and spinal cord disorders. Nat Rev
Neurol 18, 158–172 (2022).
https://doi.org/10.1038/s41582-021-00616-3
* Please contact your local Fujirebio representative for the
availability of this product in your country
Lumipulse is a registered trademark of Fujirebio Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240726266467/en/
For media: Public Relations Section, Public
Relations/Sustainability Department, H.U. Group Holdings, Inc..
Phone: +81-3-6279-0884 E-mail: pr@hugp.com
For investors and analysts: IR/SR Dept. Phone:
+81-3-5909-3337 E-mail: ir@hugp.com